Article
A phase 1 study of a meningococcal native outer membrane vesicle vaccine made from a group B strain with deleted lpxL1 and synX, over-expressed factor H binding protein, two PorAs and stabilized OpcA expression.
Vaccine - 4 Feb 2011
Keiser P B, Biggs-Cicatelli S, Moran E E, Schmiel D H, Pinto V B, Burden R E, Miller L B, Moon J E, Bowden R A, Cummings J F, Zollinger W D
Abstract excerpt
This phase I clinical trial assessed the safety and immunogenicity of a native outer membrane vesicle (NOMV) vaccine prepared from an lpxL1(-) synX(-) mutant of strain 8570(B:4:P1.19,15:L8-5) of Neisseria meningitidis. Additional mutations enhance the expression of factor H binding protein variant 1 (fHbp v.1), stabilize expression of OpcA and introduce a second PorA (P1.22,14). Thirty-six volunteers were...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.